{
    "root": "6620c4ee-16f6-4513-a8c1-2b47c80b6330",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "AJOVY",
    "value": "20250325",
    "ingredients": [
        {
            "name": "FREMANEZUMAB",
            "code": "PF8K38CG54"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "DISODIUM ETHYLENEDIAMINEDIACETATE",
            "code": "EQL53S5L0F"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "indications": "AJOVY is indicated for the preventive treatment of migraine in adults.",
    "contraindications": "For subcutaneous use only. ( 2.1 , 2.2 ) Two subcutaneous dosing options of AJOVY are available to administer the recommended dosage: 225 mg monthly, or 675 mg every 3 months (quarterly) ( 2.1 ) The 675 mg quarterly dosage is administered as three consecutive injections of 225 mg each. ( 2.1 ) Administer in the abdomen, thigh, or upper arm subcutaneously. ( 2.2 ) See Dosage and Administration for important administration instructions. ( 2.2 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedemaÂ [see Warnings and Precautions (5.1)]."
}